Weizmann Institute Identifies Immunotherapy Targets in Drug-Resistant Prostate Cancer

/in , /by

Researchers from Israel’s Weizmann Institute of Science have unveiled a promising immunotherapy strategy that targets drug-resistant cancers by exploiting the very genetic mutations responsible for treatment failure. ​ The approach centers on a computational tool called SpotNeoMet, which scans large patient datasets to identify recurrent resistance mutations that generate neo-antigens, unique protein fragments displayed exclusively […]

Read more

Immunotherapy’s Hidden Power: Reprogramming Cancer Back to Normal

/in , /by

In a previous article, cancer reversion was introduced as the idea that malignant cells can be pushed back toward a more normal, less aggressive state instead of simply being destroyed. That earlier discussion focused mainly on epigenetic plasticity, differentiation therapy, and microenvironmental modulation as ways to coax cancer cells into behaving more like healthy tissue. […]

Read more

Newsletter 52/2025

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Here we are! Newsletter number 52, and we’re ready to start counting from 1 again! I have to say, this week felt like a holiday even for research and researchers (ah, those lazy youngsters… hahaha). I struggled a bit […]

Read more

Phase 1 Trial of Allogeneic CAR-NK Therapy for Metastatic Prostate Cancer

/in , , /by

A new clinical trial is exploring allogeneic CAR-NK cell therapy targeting PSMA for patients with metastatic castration-resistant prostate cancer, or mCRPC. This exploratory study (not yet recruiting as of late 2025), aims to assess the safety profile alongside early signs of efficacy in men whose disease has progressed despite hormone suppression and other therapies. Unlike […]

Read more

Super-Adjuvant Nanoparticles: Revolutionizing Platform Cancer Vaccination

/in , /by

Super-adjuvant nanoparticles are a new type of cancer vaccine that works much better than older versions. Scientists at the University of Massachusetts Amherst created them. Their main study came out in October 2025 in Cell Reports Medicine. These tiny particles fight cancer by waking up the body’s immune system in a smart way. They mix […]

Read more

Metabolic Blockade in Prostate Cancer: Repurposing SGLT2 Inhibitors as Dual Antitumor and Cardio-Protective Therapy

/in , , /by

SGLT2 inhibitors, familiar as diabetes medications like dapagliflozin and canagliflozin, show promise against prostate cancer (and other solid tumors) through targeted metabolic disruption that exploits cancer cells’ addiction to glucose. Prostate tumors frequently overexpress SGLT2 transporters, enabling excessive glucose uptake that fuels the Warburg effect, where cancer cells convert glucose to lactate even in oxygen-rich […]

Read more

Frog Gut Bacterium Ewingella americana Completely Eradicates Colon Tumors in Mice

/in , , /by

The Japanese tree frog, Dryophytes japonicus, has become the source of a striking experimental cancer approach via a gut bacterium, Ewingella americana, that can completely eradicate colorectal tumors in mice. Amphibians and reptiles rarely develop cancer, so researchers systematically screened 45 bacterial strains from frogs, newts, and lizards; nine showed anti-tumor activity, but E. americana […]

Read more

Newsletter 51/2025

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! I want to wish you all a Merry Christmas! We’ve almost reached Newsletter number 52, and new trials and research keep coming in. Stay strong and fight on! As usual, we also have a podcast if you prefer to […]

Read more

Allergy Cells to Deliver Oncolytic Viruses or Drugs and to Stimulate the Immune System

/in , , , /by

A team of scientists in China has found a way to turn the same type of cells that cause allergies into a new kind of weapon against cancer. Their work suggests that the body’s fastest immune reaction, normally blamed for hives and asthma, could be redirected to wake up the immune system inside tumors and […]

Read more

Phase 3 InavoPC Trial of Inavolisib for mCRPC

/in , , /by

A Phase 3 clinical trial is evaluating Inavolisib, a precision oncology drug, for men with metastatic castration-resistant prostate cancer (mCRPC).. The InavoPC trial offers a distinct approach: combining a PI3K inhibitor with continued hormonal therapy to address a fundamental biological mechanism of treatment resistance. Inavolisib is a highly selective inhibitor of the PI3Kα kinase enzyme. […]

Read more